We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Portage Biotech Inc (PRTG) NPV

Sell:$0.27 Buy:$0.28 Change: $0.015 (6.25%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$0.27
Buy:$0.28
Change: $0.015 (6.25%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$0.27
Buy:$0.28
Change: $0.015 (6.25%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Portage Biotech Inc. is a clinical-stage immuno-oncology company. The Company is advancing therapies to improve long-term treatment response and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. The Company’s portfolio consists of six diverse platforms, with programs including invariant natural killer T cell (iNKT) agonists, which includes PORT-2 and PORT-3, therapies that activate the innate and adaptive immune system. The Company’s portfolio also includes small molecule adenosine inhibitors, such as PORT-6, PORT-7, PORT-8 and PORT-9, which represent of targeting the adenosine pathway. Within these six platforms, the Company has 14 products in development with multiple clinical readouts.

Contact details

Address:
Clarence Thomas Building, Road Town
P.O. Box 4649
TORTOLA
VG1110
Virgin Islands (British)
Telephone:
+1 (416) 9291806
Website:
https://portagebiotech.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PRTG
ISIN:
VGG7185A1286
Market cap:
$4.38 million
Shares in issue:
19.78 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
Virgin Islands
Currency:
US dollar
Indices:
n/a

Key personnel

  • Ian Walters
    Chairman of the Board, Chief Executive Officer
  • Allan Shaw
    Chief Financial Officer, Secretary
  • Robert Kramer
    Chief Scientific Officer
  • Steven Innaimo
    Vice President - Project Management and Operations
  • Justin Fairchild
    Vice President - Development
  • Brian Wiley
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.